138 related articles for article (PubMed ID: 21155943)
41. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S; Choy M
Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
[TBL] [Abstract][Full Text] [Related]
42. Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Shimamoto K; Fujita T; Ito S; Naritomi H; Ogihara T; Shimada K; Tanaka H; Yoshiike N;
Hypertens Res; 2008 Mar; 31(3):469-78. PubMed ID: 18497466
[TBL] [Abstract][Full Text] [Related]
43. Aliskiren versus ramipril in hypertension.
Verdecchia P; Angeli F; Mazzotta G; Martire P; Garofoli M; Gentile G; Reboldi G
Ther Adv Cardiovasc Dis; 2010 Jun; 4(3):193-200. PubMed ID: 20418269
[TBL] [Abstract][Full Text] [Related]
44. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Tytus RH; Burgess ED; Assouline L; Vanjaka A
Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
[TBL] [Abstract][Full Text] [Related]
45. Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).
Abraham I; MacDonald K; Song M; Ciesielski G; Pacheco C; Lee C; Cholette M; Kinsey K; Speaks P; Hermans C; Brié H; Reel S; Van der Niepen P; Yee B; Vancayzeele S
Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):314-22. PubMed ID: 21930367
[TBL] [Abstract][Full Text] [Related]
46. Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.
Hathial M
Indian Heart J; 2008; 60(3):200-4. PubMed ID: 19240307
[TBL] [Abstract][Full Text] [Related]
47. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study.
Holzgreve H; Risler T; Trenkwalder P
Curr Med Res Opin; 2006 Sep; 22(9):1849-58. PubMed ID: 16968588
[TBL] [Abstract][Full Text] [Related]
49. Failure to intensify hypertension therapy after rejected aliskiren claims.
Zeng F; Park J; Plauschinat CA; Patel BV
Clin Ther; 2012 May; 34(5):1122-31. PubMed ID: 22541588
[TBL] [Abstract][Full Text] [Related]
50. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
51. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
Sever PS; Gradman AH; Azizi M
J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
[TBL] [Abstract][Full Text] [Related]
52. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis.
Takenaka T; Okayama M; Kojima E; Nodaira Y; Arai J; Uchida K; Kikuta T; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
Clin Exp Hypertens; 2013; 35(4):244-9. PubMed ID: 23534458
[TBL] [Abstract][Full Text] [Related]
53. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
54. Aliskiren in the management of hypertension.
Barrios V; Escobar C
Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828
[TBL] [Abstract][Full Text] [Related]
55. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
56. [Management of severe hypertension in France in 1999 and 2000: intermediate results of a health insurance intervention program].
Tilly B; Guilhot J; Salanave B; Fender P; Allemand H
Arch Mal Coeur Vaiss; 2002; 95(7-8):687-94. PubMed ID: 12365081
[TBL] [Abstract][Full Text] [Related]
57. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
Krupicka J; Ceypová K; Kristenová P; Hauser T
Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
[TBL] [Abstract][Full Text] [Related]
58. Use of moxonidine in elderly patients with resistant hypertension.
Martin U; Hill C; O' Mahony D
J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
[TBL] [Abstract][Full Text] [Related]
59. Aliskiren in an alternate-day administration schedule in hypertensive albuminuric patients.
Spanos G; Kalaitzidis RG; Karasavvidou DP; Zikou X; Siamopoulos KC
Blood Press Monit; 2014 Dec; 19(6):359-65. PubMed ID: 25369821
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension.
Yoshitomi Y; Kawanishi K; Yamaguchi A; Sakurai S; Minai K; Ishii T; Tarutani Y; Tsujibayashi T; Kaneki M; Saitou Y; Suwa S
Int Heart J; 2013; 54(2):88-92. PubMed ID: 23676368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
